Gene therapy for cancer therapeutics

被引:2
作者
Bilbao, G
Curiel, DT
机构
[1] UNIV ALABAMA,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294
关键词
antisense; cancer; gene therapy; infiltrate lymphocytes; intracellular single chain antibodies; ribozyme; transcriptional/transductional targeting; triplex; tumour-polynucleotide immunisation;
D O I
10.1517/13543776.6.12.1267
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This review highlights current strategies and significant developments being employed in gene therapy for neoplastic diseases. Three main approaches, mutation compensation, molecular chemotherapy and genetic immunopotentiation, have been undertaken. Mutation compensation relies on strategies to ablate activated oncogenes at the level of DNA (tripler), messenger RNA (antisense or ribozyme) or protein (intracellular single chain antibodies), and augment tumour suppressor gene expression. Molecular chemotherapy uses the delivery of a toxin gene to tumour cells for eradication. This can be accomplished by either transductional targeting, whereby the toxin is specifically delivered to the tumour, or by transcriptional targeting, whereby tumour-specific transcriptional activators are employed selectively to 'turn on' the toxin gene exclusively within the tumour. Genetic immunopotentiation refers to treatment based on the induction of a specific immune response against tumour-associated antigens (TAAs). The main objective of this therapy is to reinforce and bolster the immune system of the cancer-bearing host, resulting in rejection of the tumour.
引用
收藏
页码:1267 / 1284
页数:18
相关论文
共 145 条
[1]   RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE HUMAN ALKYLTRANSFERASE CDNA PROVIDES NITROSOUREA RESISTANCE TO HEMATOPOIETIC-CELLS [J].
ALLAY, JA ;
DUMENCO, LL ;
KOC, ON ;
LIU, L ;
GERSON, SL .
BLOOD, 1995, 85 (11) :3342-3351
[2]  
ALLIONE A, 1994, CANCER RES, V54, P6022
[3]  
AURUP H, 1994, NUCLEIC ACIDS RES, V22, P23232
[4]  
BANYA EM, 1990, NUCLEIC ACIDS RES, V18, P2977
[5]   Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice [J].
Bargou, RC ;
Wagener, C ;
Bommert, K ;
Mapara, MY ;
Daniel, PT ;
Arnold, W ;
Dietel, M ;
Guski, H ;
Feller, A ;
Royer, HD ;
Dorken, B .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2651-2659
[6]   SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX - UNRESTRICTED RECOGNITION OF TUMOR-ASSOCIATED MUCINS BY HUMAN CYTO-TOXIC T-CELLS [J].
BARND, DL ;
LAN, MS ;
METZGAR, RS ;
FINN, OJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :7159-7163
[7]  
BARNES NB, 1996, CLIN CANCER RES, V2, P1089
[8]   DEGRADATION OF MESSENGER-RNA IN EUKARYOTES [J].
BEELMAN, CA ;
PARKER, R .
CELL, 1995, 81 (02) :179-183
[9]   EFFECT OF IMMUNOMODULATORS ON SPECIFIC TUMOR-IMMUNITY INDUCED BY LIPOSOME-ENCAPSULATED TUMOR-ASSOCIATED ANTIGENS [J].
BERGERS, JJ ;
DENOTTER, W ;
DULLENS, HFJ ;
DEGROOT, JW ;
STEERENBERG, PA ;
FILIUS, PMG ;
CROMMELIN, DJA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :721-726
[10]  
BERTHIERVERGNES O, 1994, CANCER RES, V54, P2433